Fabian Pott

Fabian Pott

Auto-generated profile, based on publicly available information

Fabian Pott

Charite Univ Med Berlin, Charitepl 1, D-10117 Berlin, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2020 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
RCRobert Lorenz Chua
Robert Lorenz Chua
SLSören Lukassen
Sören Lukassen
STSaskia Trump
Saskia Trump
BHBianca P. Hennig
Bianca P. Hennig
DWDaniel Wendisch
Daniel Wendisch
RERoland Eils
Roland Eils
To investigate the immune response and mechanisms associated with severe coronavirus disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal and bronchial samples from 19 clinically well-characterized patients with moderate or critical disease and from five healthy controls. We identified airway epithelial cell types and states vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In patients with COVID-19, epithelial cells showed an average three-fold increase in expression of the SARS-CoV-2 entry receptor ACE2, which correlated with interferon signals by immune cells. Compared to moderate cases, critical cases exhibited stronger interactions between epithelial and immune cells, as indicated by ligand–receptor expression profiles, and activated immune cells, including inflammatory macrophages expressing CCL2, CCL3, CCL20, CXCL1, CXCL3, CXCL10, IL8, IL1B and TNF. The transcriptional differences in critical cases compared to moderate cases likely contribute to clinical observations of heightened inflammatory tissue damage, lung injury and respiratory failure. Our data suggest that pharmacologic inhibition of the CCR1 and/or CCR5 pathways might suppress immune hyperactivation in critical COVID-19.

27 November 2021 in Cell
Verified
Journal Article
Closed access
DWDaniel Wendisch
Daniel Wendisch
ODOliver Dietrich
Oliver Dietrich
TMTommaso Mari
Tommaso Mari
SSSaskia von Stillfried
Saskia von Stillfried
IIIgnacio L. Ibarra
Ignacio L. Ibarra
LSLeif Erik Sander
Leif Erik Sander

24 December 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
STSaskia Trump
Saskia Trump
SLSören Lukassen
Sören Lukassen
MAMarkus S. Anker
Markus S. Anker
RCRobert Lorenz Chua
Robert Lorenz Chua
JLJohannes Liebig
Johannes Liebig
ILIrina Lehmann
Irina Lehmann

11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GNGeraldine Nouailles
Geraldine Nouailles
EWEmanuel Wyler
Emanuel Wyler
PPPeter Pennitz
Peter Pennitz
DPDylan Postmus
Dylan Postmus
DVDaria Vladimirova
Daria Vladimirova
MWMartin Witzenrath
Martin Witzenrath
In COVID-19, immune responses are key in determining disease severity. However, cellular mechanisms at the onset of inflammatory lung injury in SARS-CoV-2 infection, particularly involving endothelial cells, remain ill-defined. Using Syrian hamsters as a model for moderate COVID-19, we conduct a detailed longitudinal analysis of systemic and pulmonary cellular responses, and corroborate it with datasets from COVID-19 patients. Monocyte-derived macrophages in lungs exert the earliest and strongest transcriptional response to infection, including induction of pro-inflammatory genes, while epithelial cells show weak alterations. Without evidence for productive infection, endothelial cells react, depending on cell subtypes, by strong and early expression of anti-viral, pro-inflammatory, and T cell recruiting genes. Recruitment of cytotoxic T cells as well as emergence of IgM antibodies precede viral clearance at day 5 post infection. Investigating SARS-CoV-2 infected Syrian hamsters thus identifies cell type-specific effector functions, providing detailed insights into pathomechanisms of COVID-19 and informing therapeutic strategies.

3 April 2023 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
GNGeraldine Nouailles
Geraldine Nouailles
JAJulia M. Adler
Julia M. Adler
PPPeter Pennitz
Peter Pennitz
SPStefan Peidli
Stefan Peidli
LALuiz Gustavo Teixeira Alves
Luiz Gustavo Teixeira Alves
JTJakob Trimpert
Jakob Trimpert
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.

23 February 2021 in mBio
Verified
Journal Article
Open access
PDF file
PNPatrick Niekamp
Patrick Niekamp
GGGaelen Guzman
Gaelen Guzman
HLHans C. Leier
Hans C. Leier
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
VRVeronica Richina
Veronica Richina
FTFikadu Tafesse
Fikadu Tafesse
Mycobacterium tuberculosis ( Mtb ) invades alveolar macrophages through phagocytosis to establish infection and cause disease. The molecular mechanisms underlying Mtb entry are still poorly understood.